Claim OwnershipOncology Brothers: Practice-Changing Cancer Discussions
Subscribed: 55Played: 2,402
Subscribe
© Oncology Brothers
Description
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
219 Episodes
Reverse
Welcome to the Oncology Brothers podcast! In this episode, we dived into the evolving frontline treatment landscape for triple-negative breast cancer (TNBC).
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Join us as we welcomed Dr. Sherene Loi, a leading breast medical oncologist from Australia, to discuss the challenges of treating TNBC and the exciting new treatment options available. We explored the significance of PD-L1 scoring in metastatic TNBC, the implications of recent trials like ASCENT-04, and the potential of antibody-drug conjugates (ADCs) such as sacituzumab govitecan and datopotamab deruxtecan.
Key topics included:
• The role of PD-L1 positivity in treatment decisions
• Insights from the ASCENT-04 trial and its findings
• Common side effects associated with sacituzumab and strategies for management
• The future of immunotherapy and ADCs in TNBC treatment
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable information and clinical pearls. Don't forget to subscribe for more insightful discussions on cancer treatment!
#TNBC, #PDL1positive, #ASCENT04, #Immunotherapy, #OncBrothers
In this episode of the Oncology Brothers podcast, we dived deep into the evolving landscape of HER2-positive breast cancer treatment following the significant advancements made in 2025. Joined by Dr. Virginia Kaklamani from UT Health San Antonio, we discussed the latest data from SABCS 2025 and pivotal trials such as DESTINY-Breast09, which have led to new treatment approvals and strategies.
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Key topics included:
• The treatment algorithm for early-stage HER2-positive breast cancer, including the APT trial and the role of trastuzumab.
• Insights into neoadjuvant and adjuvant therapies, including the implications of the neoCARHP trial regimen and the potential of T-DXd.
• The impact of recent studies in metastatic HER2-positive disease, including the approval of T-DXd plus pertuzumab and the promising results from the PATINA trial.
• A discussion on managing side effects and the importance of patient quality of life during treatment.
Join us for an informative conversation that highlights the latest advancements in HER2-positive breast cancer care and how they can be applied in clinical practice. Don't forget to like, subscribe, and leave a review to help us reach more healthcare professionals who can benefit from these discussions!
#HER2Positive, #BreastCancer, #SABCS25, #TDXd, #BreastCancerTreatment, #OncologyBrothers
In this episode of the Oncology Brothers podcast we navigated the rapidly evolving treatment landscape of Metastatic Hormone Receptor-Positive Breast Cancer. We were joined by Dr. Kevin Kalinsky, Director of the Breast Cancer Program at the Winship Cancer Institute, Emory University, to discuss the implications of new targeted therapies, optimal sequencing strategies, and practical toxicity management.
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
• YouTube: https://www.youtube.com/@oncologybrothers
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
The discussion covered:
• The critical role of NGS testing (tissue vs. liquid biopsy) in identifying PIK3CA, ESR1, AKT1 and PTEN alterations.
• Frontline management of high-risk, endocrine-resistant disease with the inavolisib triplet (INAVO120) and its overall survival benefit.
• Choosing between CDK4/6 inhibitors (abemaciclib vs. ribociclib) in de novo metastatic disease.
• Post-CDK4/6 inhibitors on progression we covered, the use of oral SERDs (imlunestrant) and AKT inhibitors (capivasertib).
• The "ADC explosion", sequencing T-DXd (DESTINY-Breast06), sacituzumab govitecan (TROPiCS-02), and datopotamab deruxtecan (TROPION-Breast01).
• Clinical pearls for managing toxicities: stomatitis, hyperglycemia, rash, neutropenia, and ILD.
Join us as we break down the latest data and provide actionable insights for the practicing oncologist. Don't forget to subscribe for more episodes in our breast cancer algorithm series!
#MetastaticBreastCancer, #HRPositive, #ADCsequencing, #PIK3CA-AKT, #OncologyPodcast, #OncologyBrothers
In this episode of the Oncology Brothers podcast, hosts Rahul and Rohit Gosain dived deep into the evolving landscape of breast cancer treatment algorithms, focusing on early and locally advanced hormone receptor-positive breast cancer. Joined by Dr. Erica Mayer, a breast medical oncologist at the Dana-Farber Cancer Institute.
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
• YouTube: https://www.youtube.com/@oncologybrothers/
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
The discussion covered:
• The role of chemotherapy in early-stage hormone receptor-positive breast cancer, including the use of anthracyclines versus taxane-based approaches.
• Insights from the TAILORx trial and the implications of Oncotype DX scores in treatment decisions.
• The ongoing OFSET trial and its potential impact on premenopausal patients with low recurrence scores.
• The use of CDK4/6 inhibitors, including ribociclib and abemaciclib, in the adjuvant setting, along with their side effect profiles and dosing considerations.
• The significance of the recent lidERA trial results featuring giredestrant and its implications for future treatment strategies.
Join us as we explore the latest data, treatment paradigms, and the importance of patient-shared decision-making in breast cancer care. Don't forget to subscribe for more insights and staying up to date in the field of cancer.
#EarlyBreastCancer, #OncotypeDX, #CDK46inhibitors, #OralSERD, #AdjuvantTherapy, #OncologyBrothers
In this episode of the Oncology Brothers podcast, we engaged in a thought-provoking discussion with Dr. Patrick Soon-Shiong, a pioneer in oncology and the innovator behind the approval of nab-paclitaxel (Abraxane). We delved into the exciting potential of Anktiva (N-803), an IL-15 receptor super agonist designed to expand and activate natural killer (NK) cells and CD8 T cells, with the hope of revolutionizing cancer treatment.
Dr. Soon-Shiong shared insights into the mechanism of action of Anktiva, its current approvals in non-muscle invasive bladder cancer, and extended approval in non-small cell lung cancer in Saudi Arabia, and the promising clinical trial data that suggests a significant increase in overall survival for patients. The conversation also touched on the importance of restoring lymphocyte counts and the implications for treating various tumor types.
Join us as we explore the future of immunotherapy, the challenges of regulatory approval, and the potential for Anktiva to change the landscape of cancer treatment.
Key Topics:
• Mechanism of action of Anktiva
• Current approvals and clinical trial data
• The role of lymphocyte counts in cancer treatment
• Future directions for immunotherapy
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more discussions on the latest in oncology!
#Oncology #CancerTreatment #Immunotherapy #IL15Agonist #OncologyBrothers
In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approval of T-DXd (trastuzumab deruxtecan) plus Pertuzumab for the treatment of HER2-positive metastatic breast cancer. Joined by Dr. Sara Tolaney, the lead author of the DESTINY-Breast 09 study, where we discussed the findings that show a significant improvement in progression-free survival (PFS) from 26.9 months to 40.7 months, with a hazard ratio of 0.56.
Key topics included:
• The design and findings of the DESTINY-Breast09 trial
• Comparison with traditional treatment regimen THP (trastuzumab, pertuzumab, and taxane)
• The implications of these findings for clinical practice
• The role of maintenance therapy and the potential for personalized treatment strategies
• Common side effects associated with T-DXd and pertuzumab, including ILD (Interstitial Lung Disease)
Join us as we explore the future of HER2-positive breast cancer treatment and the exciting developments that are changing the landscape for patients.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights!
#HER2positiveBreastCancer, #TrastuzumabDeruxtecan, #DestinyBreast09, #MetastaticBreastCancer, #OncologyBrothers
In this episode of the Oncology Brothers podcast, we discussed two challenging cases focused on Acute Myeloid Leukemia (AML). We welcomed Dr. Naval Daver, a leading expert from MD Anderson Cancer Center, to discuss: therapy-related AML and de novo AML where induction chemotherapy is not an option.
Episode Highlights:
• Overview of therapy-related AML and its increasing prevalence due to advancements in solid tumor treatments.
• In-depth discussion on the prognosis and treatment options for patients with complex cytogenetics.
• Comparison of induction treatments: CPX-351 vs. the traditional 7 + 3 regimen, including survival rates and side effects.
• Insights into the use of hypomethylating agents combined with venetoclax for older patients with AML, particularly those with NPM1 mutations.
• Practical considerations for administering these treatments in both inpatient and outpatient settings.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of AML management.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more discussions on treatment algorithms, conference highlights, and the latest FDA approvals!
#AcuteMyeloidLeukemia, #TherapyRelatedAML, #DeNovoAML, #TransplantIneligible, #OncologyBrothers
In this episode of the Oncology Brothers podcast, we dived into the current treatment landscape for head and neck cancer. We welcomed Dr. Fangdi Sun, a head and neck medical oncologist from Stanford University, to discuss key topics including:
• The importance of initial workup and the role of biomarkers, including HPV and EBV testing.
• Treatment paradigm for early-stage and locally advanced head and neck cancers, focusing on the differences between HPV-positive and HPV-negative disease.
• The evolving role of immunotherapy and the new perioperative approaches in treatment.
• Insights into managing metastatic disease, including the use of PD-L1 scores and systemic therapy options.
• The significance of multidisciplinary collaboration in optimizing patient care.
Whether you're a healthcare professional or simply interested in oncology, this episode provides valuable insights into the complexities of head and neck cancer treatment. Don't miss out on this informative discussion!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Subscribe to our channel for more episodes as we continue to bridge the gap in oncology!
#HeadAndNeckCancer, #HPV, #Immunotherapy, #MultidisciplinaryCare, #OncologyBrothers
In this episode of the Oncology Brothers podcast, we dived into the recent FDA approval of daratumumab for high-risk smoldering myeloma, based on the groundbreaking AQUILA study. We were joined by Dr. Vincent Rajkumar, a world-renowned myeloma specialist, who provided valuable insights into the complexities of smoldering myeloma, its risk stratification, and the implications of early intervention.
Key topics discussed included:
• The definition and classification of smoldering myeloma
• The design and findings of the AQUILA trial
• The significance of time to progression and overall survival in treatment
• The risk-benefit analysis of daratumumab therapy, including potential side effects
• Future directions in myeloma treatment and ongoing research
Join us for an informative discussion as we bridge the gap between academic research and community practice, helping healthcare professionals and patients navigate the evolving landscape of myeloma treatment.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, conference highlights, and FDA approvals!
Feeling overwhelmed by the rapid pace of change in multiple myeloma? ASH 2025 delivered potentially practice-changing data that could redefine second-line therapy and beyond.
In this episode, we sat down with myeloma specialist Dr. Ben Derman from the University of Chicago to dissect the most critical studies. We moved from the controversial treatment of high-risk smoldering myeloma to head-to-head comparisons in newly diagnosed disease, and finally, to the groundbreaking bispecific antibody data that is set to revolutionize care at first relapse.
Key topics covered in this episode:
● AQUILA update: Daratumumab in high-risk smoldering myeloma, and the ongoing clinical dilemma
● COBRA: Is KRD superior to VRD in newly diagnosed multiple myeloma? Unpacking the MRD and PFS data.
● TecLILLE: A first look at Teclistamab + Daratumumab in frontline, transplant-ineligible patients.
● MajesTEC-3: PFS and OS data for Teclistamab + Daratumumab in first relapse, and its impending FDA approval.
Tune in for this expert breakdown to navigate the new myeloma landscape with confidence.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Subscribe for more deep dives into treatment algorithms and major conference highlights!
#OncologyBrothers #ASH2025 #MultipleMyeloma #Myeloma #SmolderingMyeloma #BispecificAntibody #Teclistamab #Daratumumab #CART
We’re kicking off 2026 with practice-changing data fresh from GI ASCO 2026. In this episode, we were joined once again by Dr. Rachna Shroff from the University of Arizona Cancer Center to break down the four most pivotal studies in upper GI and colorectal cancers presented at the GI ASCO 2026.
We dived into the latest updates that will directly impact your clinical decisions, from new standards in perioperative therapy to revolutionary front-line regimens for metastatic disease.
Key topics covered in this episode:
● MATTERHORN update: Surgical outcomes & FLOT modifications with Durvalumab in resectable gastric/GEJ cancer
● HERIZON-GEA-01: Zanidatamab + chemo + Tislelizumab the new frontline standard for HER2+ gastric cancer
● BREAKWATER: Confirming Encorafenib + Cetuximab + chemo (FOLFOX or FOLFIRI) for BRAF V600E mCRC
● COMMIT: Chemo + Atezolizumab vs. Atezolizumab alone in MSI-H/dMMR metastatic colorectal cancer
Tune in for this dense, insightful recap and stay ahead of the curve.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don’t forget to subscribe for more expert analysis on treatment algorithms and major conference highlights!
#OncologyBrothers #GI26 #GastricCancer #ColorectalCancer #HER2 #BRAF #MSI #OncologyPodcast
In this episode of the Oncology Brothers podcast, we were joined by Dr. Julie Vose, a leading expert in lymphoma from the University of Nebraska Medical Center. Together, we delved into the key abstracts presented at ASH 2025, focusing on significant studies in lymphoma and chronic lymphocytic leukemia (CLL).
Episode Highlights:
● EPCORE FL-1: the approval of Epcoritamab in combination with Rituximab and lenalidomide for relapsed refractory follicular lymphoma
● CLL-17: comparison between continuous BTK inhibitors and fixed-duration venetoclax with obinutuzumab
● BRUIN CLL-313: insights into the non-covalent BTK inhibitor, pirtobrutinib, and its effectiveness in the frontline setting compared to traditional treatments
● S1826: a three-year update on the use of Nivolumab-AVD versus BV-AVD in advanced-stage Hodgkin's lymphoma, showcasing improved PFS and better tolerability
Join us as we unpack these practice-changing studies and discuss their implications for community oncologists.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more insights and highlights from oncology conferences!
#ASH25 #Oncology #Hematology #Lymphoma #CLL #CancerResearch
In this episode of the Oncology Brothers podcast, we dived into the key highlights from ASH 2025, focusing on advancements in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).
We welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss key studies from the leukemia space, including the PARADIGM trial comparing Azacitidine plus Venetoclax to traditional 7 + 3 induction chemotherapy for fit patients with newly diagnosed AML. We explore the implications of these findings, the potential for hypomethylating agents in treatment regimens, and the evolving landscape of CML therapies, including the promising results from the ASK4FIRST/ASK2ESCALATE featuring Asciminib.
Key topics covered in this episode:
● The PARADIGM trial and its impact on AML treatment strategies
● Real-world evidence on shortened venetoclax dosing
● The role of menin inhibitors in combination therapies
● Patient-reported outcomes and quality of life with asciminib in CML
Tune in for an insightful discussion on the future of leukemia treatment and the importance of patient-centered care.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more updates on treatment algorithms, recent approvals, and conference highlights!
#OncologyBrothers #ASH2025 #ASH25 #AML #CML #Leukemia #Hematology
Join us as we dive into the latest advancements in HER2-positive breast cancer from SABCS 2025. In this episode, we discussed key studies including DESTINY Breast-11 and DESTINY Breast-05, highlighting their implications for neoadjuvant and adjuvant treatments. We also explored the HER2CLIMB-05 trial and the recent approval of TDXD with pertuzumab in frontline settings for metastatic HER2-positive disease.
Special guest Dr. Harold Burstein from Dana-Farber Cancer Institute shared his insights on the evolving landscape of HER2-positive breast cancer treatment, including the importance of patient selection and the management of side effects like interstitial lung disease (ILD).
Tune in for a comprehensive recap of the latest data, treatment algorithms, and how these advancements are changing the lives of patients with HER2-positive breast cancer.
Don't forget to like, subscribe, and check out our other episodes for more updates on treatment options and conference highlights!
Topics Covered:
• DESTINY Breast-11 and its impact on neoadjuvant therapy
• Insights from DESTINY Breast-05 on adjuvant treatment for high-risk residual disease
• HER2CLIMB-05 trial findings and implications for metastatic disease
• The role of T-DXd with pertuzumab in frontline settings
• The PATINA trial and its significance for triple-positive metastatic breast cancer
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, recent approvals, and conference highlights!
#SABCS2025 #HER2positive #DestinyTrials #OncologyBrothers #BreastCancer
In this episode of the Oncology Brothers podcast, we were joined by Dr. Rebecca Shatsky, a breast medical oncologist and director of the Inflammatory and Triple Negative Breast Cancer Program at UC San Diego. We dived into the latest findings from the SABCS 2025 conference, focusing on key studies related to triple negative breast cancer (TNBC).
Join us as we discussed:
* The RJBC 1501 study, which explored the role of carboplatin in high-risk early-stage TNBC and its impact on disease-free survival.
* Insights from the CITRIN study, which questions the carboplatin paradigm and highlights modern treatment approaches.
* The TBCRC-056 and OlympiaN trials, investigating the combination of PARP inhibitors and immunotherapy in patients with germline BRCA and PALB2 mutations.
We unpacked the implications of these studies for clinical practice, including the potential benefits and challenges of incorporating carboplatin and novel therapies into treatment regimens.
Tune in for an informative discussion that aims to keep you updated on the evolving landscape of breast cancer treatment!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights from the world of oncology!
#SABCS2025 #TNBC #PARPinhibitors #BRCAmutation #ChemoFree #OncologyBrothers #BreastCancer #SABCS25
Join us for another insightful episode of the Oncology Brothers podcast, where we dived into the latest advancements in bladder cancer treatment! In this episode, we discussed the groundbreaking approval of Enfortumab vedotin (EV) combined with Pembrolizumab (Pembro) for cisplatin-ineligible muscle-invasive bladder cancer, based on the impressive results from the Keynote-905/EV-303 study.
We are thrilled to have Dr. Tom Powles, a world-renowned GU medical oncologist, share his expertise on the study design, findings, and implications for patient care. Discover how this new standard of care is transforming treatment options, improving event-free survival, and overall survival rates for patients.
Key topics covered in this episode included:
• Overview of the Keynote-905/EV-303 study and its significance
• Comparison with previous studies like the NIAGARA trial
• Discussion on the side effects of EV Pembro and management strategies
• The role of ctDNA in guiding post-operative therapy
• Future directions in bladder cancer research and upcoming trials
Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more practice-changing updates in oncology!
#BladderCancer #Keynote905 #ADC #Immunotherapy #OncologyBrothers #GUOncology #MIBC
Welcome to the Oncology Brothers podcast! In this episode, we dived into the key highlights from the SABCS 2025 conference, focusing on metastatic hormone receptor-positive breast cancer.
Join us as we discussed:
• The role of CDK4-6 inhibitors in frontline therapy, featuring updates from the AMBRE and MONALEESA-3 studies
• Insights into second-line treatment options, including the VIKTORIA-1, evERA, EMBER-3, SERENA-6 trials
• A critical look at the ASCENT-07 study, exploring the role of antibody-drug conjugates (ADCs) in endocrine-resistant disease
We were thrilled to have Dr. Hope Rugo, a world-renowned breast medical oncologist from City of Hope, share her expertise and insights on these pivotal studies.
Tune in for an informative discussion that unpacks the latest advancements in treatment options for metastatic hormone receptor-positive breast cancer, and learn how these findings may impact clinical practice.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, recent approvals, and conference highlights!
#SABCS2025 #MBC #HRpositive #CDK46 #ADCs #OncologyBrothers
In this episode of The Oncology Brothers, we were joined by Dr. Laura Huppert from UCLA to discuss the latest practice-changing findings from the SABCS 2025 conference, focusing on early-stage hormone receptor-positive breast cancer.
Join us as we dive into three key abstracts:
1. ALTTO Study: Discover the results comparing aromatase inhibitors to tamoxifen in triple-positive breast cancer and the implications for treatment strategies.
2. lidERA Study: Learn about the promising data on the oral selective estrogen receptor degrader (SERD) giredestrant, which shows significant improvement in invasive disease-free survival compared to standard endocrine therapy.
3. NATALEE Trial: Get insights into the five-year update on ribociclib in combination with aromatase inhibitors, highlighting its benefits across different patient subgroups (stages, nodal status).
We explored the evolving landscape of endocrine therapy, the importance of side effect profiles, and how these findings may influence clinical practice moving forward.
Don't miss this informative discussion that could reshape your approach to treating early-stage hormone receptor-positive breast cancer!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Subscribe to our channel for more updates on treatment algorithms, recent approvals, and conference highlights.
#SABCS2025 #BreastCancer #AdjuvantTherapy #Giredestrant #Ribociclib #AI #OncologyBrothers #HRpositiveBC
In this episode of the Oncology Brothers podcast, we dived into the latest discussions surrounding metastatic colorectal cancer, focusing on treatment strategies for refractory cases. We recapped our recent discussions with GI experts, including Dr. John Strickler, Dr. Chiara Cremolini, Dr. Namrata Vijayvergia, and Dr. Tiago Biachi.
Key topics included:
* The importance of next-generation sequencing (NGS) and biomarker testing in treatment planning.
* An overview of second-line treatment options such as Tas-102 with Bevacizumab, Regorafenib, and Fruquintinib, along with their respective clinical trial data.
* Insights into side effect management and quality of life considerations for patients undergoing palliative treatment.
* A discussion on the recent STELLAR-303 study and its implications for immunotherapy in colorectal cancer.
Join us as we bridge the gap between academia and community practice, emphasizing the need for improved treatment options and patient care in the realm of refractory colorectal cancer.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more practice-changing updates!
#ColorectalCancer #mCRC #TAS102 #Regorafenib #PalliativeCare #OncologyBrothers #GIOcology
In this episode of the Oncology Brothers podcast, we are joined by Dr. Komal Jhaveri, a breast medical oncologist at Memorial Sloan Kettering, to discuss the evolving landscape of metastatic hormone receptor positive breast cancer, particularly focusing on low and ultra-low HER2 expression.
Key topics include:
• The significance of the DESTINY Breast-04 and DESTINY Breast-06 studies and their impact on treatment options.
• The definition and implications of low and ultra-low HER2 expression in clinical practice.
• The importance of HER2 testing and the dynamic nature of HER2 expression in tumors.
• Treatment sequencing strategies, including the use of antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (TDXd) and sasituzumab govitecan.
• Management of treatment-related toxicities, including ILD, nausea, and alopecia.
Join us for an insightful discussion that aims to keep healthcare professionals updated on the latest advancements in cancer care.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes and insights!
Comments
Download from Google Play
Download from App Store
United States